Anixa Biosciences price to sales ratio ANIX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 195×; May 2022
Peer median: 1.4×

Anixa Biosciences' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-07-31 is missing, so twelve months can't be added up.

It was last meaningful in May 2022, at 195×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	195×	151×	198×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	2.9×	1.8×	3.0×
2015	2.8×	1.9×	4.4×
2014	148×	130×	186×
2013	159×	26.5×	198×
2012	22.5×	9.2×	42.4×

Against its peers

Companies in Drug Manufacturers - General nearest Anixa Biosciences' size, closest first, today.

Company	Price to sales ratio
ANIXAnixa Biosciences	n/m
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
NATRNatures Sunshine Products	0.4×
ATNMActinium Pharmaceuticals	n/m
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Anixa Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.